DSM entered into a deal with the Australian government in Queensland to create a 70,000 sq ft CMO for mammalian cell culture. The goverment will provide the funding and DSM will provide the design and technical expertise.
DSM will also make its XD and DSP optimization methods available to CMO clients. DSM will also offer Crucell's Per.C6 cell line for use in recombinant protein and MAb production.
The facilty will come on line in 2013. It is part of the Queensland Translational Research Institute (TRI) which is being scoped to provide discovery, production and clinical testing services at one site.
DSM says the new facility forms an important part of its overall CMO strategy.
Posted by Bruce Lehr May 3rd 2010.
Comments